All In Biotech

Investigational drug · Phase 2

CNMAu8

Also called: gold nanocrystals

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis, Multiple Sclerosis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

4

Any phase or sponsor naming "CNMAu8"

First trial start

2019

Dec 19, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CNMAu8", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Amyotrophic Lateral Sclerosis
  • Multiple Sclerosis

Approved drugs for the same conditions: Multiple sclerosis · ALS (amyotrophic lateral sclerosis) · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "CNMAu8" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 445 on PubMed

Also in development for Amyotrophic Lateral Sclerosis

  • MasitinibAB1010Phase 33 trials

    AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease

  • SPG302TazbentetolPhase 33 trials

    Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis

  • PridopidinePhase 32 trials

    Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease

  • ION363Phase 31 trial

    Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis

  • MN-166ibudilastPhase 31 trial

    MediciNova · Amyotrophic Lateral Sclerosis

  • AMT-162Phase 21 trial

    UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis

  • AP-101Phase 21 trial

    AL-S Pharma · Amyotrophic Lateral Sclerosis

  • BIIB147Phase 21 trial

    Biogen · Amyotrophic Lateral Sclerosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.